key: cord-1031154-vdwragg3
authors: Hager, K. J.; Marc, G. P.; Gobeil, P.; Diaz, R. S.; Heizer, G.; Llapur, C.; Makarkov, A. I.; Vasconcellos, E.; Pillet, S.; Riera, F.; Bhutada, K.; Wolff, P. G.; Wallace, G.; Aazami, H.; Jones, C. E.; Polack, F. P.; Atkins, J.; Boulay, I.; Dhaliwall, J.; Charland, N.; Couture, M.; Jiang-Wright, J.; Landry, N.; Lapointe, S.; Lorin, A.; Mahmood, A.; Moulton, L. H.; Pahmer, E.; Parent, J.; Saxena, P.; Seguin, A.; Tran, L.; Breuer, T.; Ceregido, M. A.; Koutsoukos, M.; Roman, F.; Namba, J.; D'Aoust, M.-A.; Trepanier, S.; Kimura, Y.; The CoVLP Study Team,; Ward, B. J.
title: Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
date: 2022-01-26
journal: nan
DOI: 10.1101/2022.01.17.22269242
sha: e35b91c918a8b76fb1cb1ceb174f3487a1f229bb
doc_id: 1031154
cord_uid: vdwragg3

Background: Several COVID-19 vaccines are currently being deployed but supply constraints, concerns over durability of immune responses, solidifying vaccine hesitancy/resistance and vaccine efficacy in the face of emerging variants mean that new vaccines continue to be needed to fight the ongoing pandemic. The vaccine described here is an enveloped, coronavirus-like particle produced in plants (CoVLP) that displays the prefusion-stabilized spike (S) glycoprotein of SARS-CoV-2 (ancestral Wuhan strain) and is adjuvanted with AS03 (CoVLP+AS03). Methods: This Phase 3 randomized, observer-blind, placebo-controlled trial was conducted at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA. Adults [≥]18 years of age including those at high risk for COVID-19 complications were randomly assigned 1:1 to receive two intramuscular injections of CoVLP (3.75 g) adjuvanted with AS03 or placebo, 21 days apart. The primary efficacy endpoint was prevention of symptomatic ([≥] 1 symptom), PCR-confirmed SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of [≥]160 virologically-confirmed cases. Tolerability and safety of CoVLP+AS03 were also determined. Results: A total of 24,141 volunteers were randomly assigned 1:1 to receive vaccine or placebo (N= 12,074 and 12,067, respectively: median age 29, range 18 to 86 years). Overall, 83% received both doses. 14.8% were SARS-CoV-2 seropositive at baseline. Symptomatic SARS-CoV-2 infection was confirmed in 165 study participants in the intention to treat (ITT) set and 157 in the per-protocol population (PP) set. Of the 157 in the PP set, 118 COVID-19 cases were in the placebo group and 39 COVID-19 cases were in the CoVLP+AS03 group for an overall vaccine efficacy (VE) of 71.0% (95% confidence interval (CI) 58.6, 80.0). Moderate-to-severe COVID-19 occurred in 8 and 32 participants in the CoVLP+AS03 and placebo groups, respectively: VE 78.1% (95% CI: 53.9, 90.5) in the PP set overall and 84.5% (95% CI: 62.0, 94.7) in those seronegative at recruitment. To date, 100% of the sequenced strains (122/165 cases: 73.39%) were variants, dominated by Delta (45.9%) and Gamma (43.4%) strains. Vaccine efficacy by variant was 75.3% (95% CI 52.8, 87.9) against Delta and 88.6% (95% CI 74.6, 95.6) against Gamma. Cross-protection was also observed against Alpha, Lambda and Mu variants; although fewer cases were identified, all were in the placebo group. At diagnosis, viral loads in the CoVLP+AS03 breakthrough cases were >100-fold lower than in the placebo cases. Reactogenicity data for solicited adverse events (AEs) was analysed for a subset (N=4,136 in vaccine arm and N=3,683 for placebo) of participants. Reactogenicity was mostly mild to moderate, and transient, and occurred more frequently in the CoVLP+AS03 group. The safety analysis set used for unsolicited AE assessment comprised 24,076 participants who received at least one study injection: 12,036 received CoVLP+AS03 and 12,040 received placebo. All serious adverse events were assessed as unrelated, except two events reported in the same subject in the placebo group. No significant imbalance or safety concern was noted in medically attended AEs (MAAEs), adverse event of special interest (AESIs), AEs leading to withdrawal, deaths, or adverse events potentially associated with currently authorized vaccines. Conclusions: The CoVLP+AS03 vaccine candidate conferred an efficacy of 71.0% in preventing symptomatic SARS-CoV-2 infection caused by a spectrum of variants. Vaccine efficacy of 78.1% was observed against moderate and severe disease, while variant-specific efficacy ranged from 75.3% to 100%. Markedly lower viral loads in the CoVLP+AS03 group at the time of diagnosis suggests a significant virologic impact of vaccination even in the breakthrough cases. CoVLP+AS03 vaccine candidate was well tolerated, and no safety concerns were identified during the study. If approved by regulators, this more traditional protein+adjuvant vaccine produced using the novel plant-based platform may be able to make an important contribution to the global struggle against the increasingly complex family of SARS-CoV-2 viruses (Funded by Medicago with grants from the governments of Quebec and Canada; NCT04636697).

5 events (AEs) was analysed for a subset (N=4,136 in vaccine arm and N=3,683 for placebo) of 85 participants. Reactogenicity was mostly mild to moderate, and transient, and occurred more 86 frequently in the CoVLP+AS03 group. The safety analysis set used for unsolicited AE 87 assessment comprised 24,076 participants who received at least one study injection: 12,036 88 received CoVLP+AS03 and 12,040 received placebo. All serious adverse events were assessed 89 as unrelated, except two events reported in the same subject in the placebo group. No 90 significant imbalance or safety concern was noted in medically attended AEs (MAAEs), 91 adverse event of special interest (AESIs), AEs leading to withdrawal, deaths, or adverse events 92 potentially associated with currently authorized vaccines. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022.

Introduction 105 Since its emergence in late 2019 1 , the severe acute respiratory syndrome coronavirus 2 (SARS- 106 CoV-2) has caused more than 312 million cases of coronavirus disease 2019 (COVID- 19) 119 Several vaccines have since been deployed around the world with considerable success 8-10 and 120 acceptable safety profiles despite some concerns regarding rare cases of myocarditis and 121 pericarditis after mRNA vaccines 11 and thrombotic events associated with some adenovirus 122 vectored vaccines 12 which have been added to the prescribing information. However, the 123 reduced protection reported more recently, from clinical trials and subsequent real-world data 124 [13] [14] [15] [16] [17] , may be due to a combination of reduced cross-reactivity of vaccine-induced antibodies 125 against emerging SARS-CoV-2 variants and waning vaccine-induced humoral immunity with 126 time, especially for mild disease 18, 19 . A third dose (booster) of the mRNA vaccines has been 127 reported to restore serum NAb levels and improve cross-protection against emerging variants, 128 especially against the most severe outcomes 20 . Tensions created by the simultaneous demand 129 for booster doses in countries with largely immunized populations and the need to provide 130 primary vaccination to the majority of the world's unvaccinated populations 6,21,22 emphasize 131 the need for additional vaccines and vaccine suppliers to fully meet the global demand. 132 Alternative vaccine options that can be used under routine storage and handling conditions (2-133 8°C) or that can overcome the concerns of individuals who hesitate to get vaccinated with 134 currently licensed vaccines based on novel platform technologies due to medical conditions or 135 beliefs 23 would also be useful. 136 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. during an evolving pandemic environment with active circulation of several variants of concern 164 and of interest, as well as increasing vaccine roll-out. 165 166 167 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. identified. In parallel an unblinded medical monitor was reviewing unblinded data on a real 198 time basis to escalate to the IDMC if a stopping rule was met. The safety and efficacy data were 199 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.17.22269242 doi: medRxiv preprint 9 also reviewed by the IDMC, to confirm that the primary efficacy endpoint had been met, and 200 that the benefit/risk profile was positive. 201 The trial is ongoing and, at the time of writing, the investigators remained unaware of 202 participant-level treatment assignments. Limited team members have unblinded access to the 203 data to facilitate submission of clinical safety findings to regulatory agencies and the IDMC. 204 All other trial staff and participants remain unaware of treatment assignments. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. COVID-19 case to be considered as a primary endpoint, symptoms had to start 7 or more days 290 after second dose and before the subject was unblinded to study treatment or was administered 291 a currently deployed COVID-19 vaccine. Symptom start was required to occur on or before 292 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. August 20 th , 2021, to be included in the analysis of the primary endpoint. The IDMC 293 subcommittee provided confirmation that a COVID-19 case met the requirements for the 294 primary endpoint and assessed severity according to FDA criteria 45 . 295 Vaccine efficacy was calculated as 100 × (1incidence rate ratio) where the incidence rate 296 ratio is defined as the ratio of person-years rate of COVID-19 cases in the CoVLP+AS03 group 297 relative to the COVID-19 cases in the placebo group. For both analysis sets, censoring was 298 performed at the earlier of any of the following events, namely, when the subject experienced 299 their first virologically confirmed COVID-19 case (date of first symptoms), the study database 300 was frozen for the primary analysis, the date subject was unblinded, the date subject received 301 an approved or authorized COVID-19 vaccine, or the date of subject completion/withdrawal 302 from the study. The VE success criterion for the primary efficacy endpoint was defined as a 303 ≥50 %-point estimate and a >30 % lower limit of the 95% CI. Assuming the number of cases in 304 each arm followed a Poisson distribution, then conditioning on the total number of cases and 305 the ratio of person-time of follow up, the exact 95% CIs for the incidence rate ratio (IRR), and 306 hence for VE = 1-IRR, was obtained assuming a binomial distribution with mid-P adjustment 307 46 . Vaccine efficacy for the secondary endpoints was analyzed using the same methods as for 308 the primary endpoint, except for VE success criterion being defined as >0% lower limit of the 309 95% CI. Cumulative incidence curves were calculated using the Kaplan-Meier method. 310 Median differences in viral load values measured as log10 copies/mL were compared between 311 subjects who received CoVLP+AS03 or placebo by strain and overall using the Wilcoxon rank-312 sum test. Viral load values under the detection limit (log10 2.08) were set to half of that limit. 313 314 315 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.17.22269242 doi: medRxiv preprint 15 primary efficacy endpoint was defined as a ≥50 % point estimate and a lower limit of the 95% 380 CI >30%. These primary outcome criteria were met in both the ITT and PP sets. 381 As shown in Figure 3 for the PP set and in Supplementary Table S3 for the ITT set, VE of   382 CoVLP+AS03 was also separately evaluated in healthy participants 18-64 years of age, healthy 383 participants ≥ 65 years of age, and participants ≥ 18 years of age with significant comorbidities. 384 The VE point estimates in the PP set were 70.9% (95% CI: 57.7, 80.4) and 76.8% (95% CI: (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. Table S6 ) and then from day 43 to day 474 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S9 ). There were no deaths related to the vaccine in the study. 489 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. adjudicated to be mild and interestingly, the viral loads in these cases in either group were at or 517 near the limit of detection of the RT-qPCR assay used (log10 2.08 copies/mL) with a mean value 518 ~3715x lower than the PCR + Seq + cases in the placebo group (log10 5.65 copies/mL: Figure 5 ). 519 These observations suggest that the overall VE point estimate for CoVLP+AS03 was, at least to 520 some extent, drawn down by mild, PCR + Seqbreakthrough cases with very low viral loads. 521 Indeed, the VE point estimate for the very mild, PCR + Seqcases was -75.3% (95% CI: -364.0, 522 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.17.22269242 doi: medRxiv preprint 21 designed to target the ancestral (Wuhan) strain of SARS-CoV-2 but not a single case of 556 COVID-19 caused by this strain was identified in the current study. This trial, along with 557 Clover's recently announced global study and Novavax's regional studies, are among the first 558 Phase 3 RCTs to be confronted by a variant-dominant environment 17,56 . Although vaccines 559 developed during the first waves of the pandemic reported vaccine efficacies as high as 95% (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. suggesting that protection against the more severe manifestations of COVID-19 caused by a 636 range of variants was substantial. This study is still ongoing, and a wide range of secondary 637 outcomes will be reported as the data become available. 638 The primary vaccine efficacy and safety data presented here demonstrate that substantial 639 protection against a range of VoC can be provided by two doses of CoVLP+AS03. New cases 640 continue to be identified in the ongoing Phase 3 study and the efficacy of this new candidate 641 vaccine against the recently-emerged Omicron variant will be determined in the coming 642 months. Overall, the vaccine was generally well-tolerated and no safety signals were detected 643 during the study. Once approved by regulators, this more traditional protein+adjuvant vaccine 644 produced using the novel plant-based platform may be able to make an important contribution 645 to the global struggle against the increasingly complex family of SARS-CoV-2 viruses. 646 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.17.22269242 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.17.22269242 doi: medRxiv preprint

A pneumonia outbreak associated with a new 768 coronavirus of probable bat origin

Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective Viruses

Structure of the SARS-CoV-2 spike receptor-binding domain 774 bound to the ACE2 receptor

Mechanisms of SARS-CoV-2 entry into cells

SARS-CoV-2 variants, spike mutations 778 and immune escape

Safety and Efficacy of the BNT162b2 mRNA

Covid-19 Vaccine

The impact of vaccination on COVID-19 782 outbreaks in the United States

The success of SARS-CoV-2 vaccines and challenges ahead

COVID-19 and myocarditis: a 788 systematic review and overview of current challenges

Thrombotic 790 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Impact of the Delta variant on vaccine efficacy and 792 response strategies

The efficacy of COVID-19 vaccines against the

1.617.2 (delta) variant

Comparing COVID-796 19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and 797 variants of concern: A narrative review

Efficacy of NVX-CoV2373 Covid-19 Vaccine 801 against the B.1.351 Variant

Durability of mRNA-1273 vaccine-induced 803 antibodies against SARS-CoV-2 variants

Safety and Efficacy of the BNT162b2 805 mRNA Covid-19 Vaccine through 6 Months

Effectiveness of a third dose of the BNT162b2 807 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Global access to COVID-19 810 vaccines: a scoping review of factors that may influence equitable access for low and middle-811 income countries

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

COVID-19 Vaccine Hesitancy-A Scoping 816 Review of Literature in High-Income Countries

Virus-like particles in 818 vaccine development

Preclinical and clinical development of plant-820 made virus-like particle vaccine against avian H5N1 influenza

Humoral and cell-mediated immune responses to 822 H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE 823 adjuvants in a Phase 2 clinical trial

Immunogenicity and safety of a quadrivalent 825 plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical 826 trials in 18 to 49 and ≥50 years old adults

Efficacy, immunogenicity, and safety of a 830 plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and 831 older adults (≥65 years): two multicentre, randomised phase 3 trials. The Lancet

The production of hemagglutinin-based 833 virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

Adjuvant System AS03 containing α-836 tocopherol modulates innate immune response and leads to improved adaptive immunity

Different Adjuvants Induce Common Innate 839

Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in 840 Humans

Transcriptional profiles of adjuvanted hepatitis B

AS03-Adjuvanted H5N1 Avian Influenza

Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear 846 Cells

Adjuvanting a subunit COVID-19 848 vaccine to induce protective immunity

AS03-adjuvanted H5N1 vaccine 850 promotes antibody diversity and affinity maturation, NAI titers

Antigen sparing and cross-853 reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a 854 randomised controlled trial

H5N1 influenza vaccine formulated 856 with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses

Antibody avidity, persistence, and response 859 to antigen recall: comparison of vaccine adjuvants

Safety of AS03-adjuvanted influenza 861 vaccines: A review of the evidence

Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and 864

Older Adults Aged 65 and Older

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Adaptive immunity to SARS-CoV-2 and COVID-19

US CDC Real-Time Reverse Transcription PCR 870 Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. CDC-Emerging 871

COVID-19 Vaccine Effectiveness by 877 Product and Timing in New York State

Impact of viral load at admission on 883 the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection

SARS-CoV-2 infection: Initial viral load (iVL) 886 predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients 887 corresponds with slowing of the pandemic

Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses

Kinetics of viral load and antibody response in 892 relation to COVID-19 severity

Effect of Delta variant on viral burden 894 and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Clover BioPharmaceuticals. Clover's COVID-19 Vaccine Candidate Demonstrates 898 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of 899 Concern and Interest

SARS-CoV-2 Vaccine

CoV-2 and prevention of reinfection

Effectiveness and safety of SARS-CoV-2 vaccine in real-905 world studies: a systematic review and meta-analysis

Structural and 907 functional insights into the spike protein mutations of emerging SARS-CoV-2 variants

Significantly reduced abilities to cross-neutralize SARS-CoV-910 2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains

Safety and Efficacy of NVX-CoV2373 Covid-913

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Safety, immunogenicity and protection 918 provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like 919 particle vaccine candidate for COVID-19 in non-human primates

Should Take Efficiency of Distribution into Consideration

Recalling the universal health coverage vision and equity 926 in the COVID-19 vaccine distribution plan

Emerging manufacturers engagements in the 928 COVID -19 vaccine research, development and supply

Safety and immunogenicity of seven 932 COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or

BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled

Durability and Cross-Reactivity of Immune 936 Responses Induced by an AS03 Adjuvanted Plant-Based Recombinant Virus-Like Particle 937 Vaccine for

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Medicago Inc. is committed to providing access to anonymized data collected during the trial 671 that underlie the results reported in this article, at the end of the clinical trial, which is currently 672 scheduled to be 1 year after the last participant is enrolled, unless granted an extension. 673 Medicago Inc. will collaborate with its partner (GlaxoSmithKline, Wavre, Belgium) on such 674 requests before disclosure. Proposals should be directed to wardb@medicago.com or 675 daoustma@medicago.com. To gain access, data requestors will need to sign a data access 676 agreement and access will be granted for non-commercial research purposes only. 677 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 26, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.17.22269242 doi: medRxiv preprint